Immunoprophylaxis using intravenous (IV) hepatitis B immune globulin (HBIG) decreases the recurrence of hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT). However, IV HBIG is expensive, has significant side effects, and is inconvenient to administer. An alternative appro
Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation
โ Scribed by G Ferretti; M Merli; S Ginanni Corradini; V Callejon; P Tanzilli; A Masini; S Ferretti; M Iappelli; M Rossi; D Rivanera; D Lilli; C Mancini; A Attili; P Berloco
- Book ID
- 116929699
- Publisher
- Elsevier Science
- Year
- 2004
- Tongue
- English
- Weight
- 73 KB
- Volume
- 36
- Category
- Article
- ISSN
- 0041-1345
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Patients undergoing liver transplantation for hepatitis B-related liver disease are prone to recurrence. The mainstay of prophylaxis has been passive immunotherapy with hepatitis B immune globulin (HBIG). Antiviral therapy with lamivudine has proven effective in lowering hepatitis B virus (HBV) DNA
Current protocols for prophylaxis against allograft reinfection after liver transplantation for chronic hepatitis B virus (HBV) infection include the administration of large doses of hepatitis B immune globulin (HBIG), with considerable associated economic costs. Monotherapeutic prophylaxis with lam